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ABSTRACT
IMPLEMENTATION OF RISK MANAGEMENT IN THE MEDICAL DEVICE
INDUSTRY
by Rachelo Dumbrique
This study looks at the implementation and effectiveness of risk management
(RM) activities in the medical device industry. An online survey was distributed to
medical device professionals who were asked to identify RM-related activities performed
during the device life cycle. RM activities and techniques included Establishing Risk
Acceptance Criteria, Hazard Identification, Human Factors/Usability, Fault Tree Analysis
(FTA), Design Failure Mode and Effects Analysis (DFMEA), Process Failure Mode and
Effects Analysis (PFMEA), Hazard and Operability Study (HAZOP), Hazard Analysis
and Critical Control Point (HACCP), Risk Benefit Analysis, and Risk Assessment of
Customer Complaint. Devices were identified by type (therapeutic, surgical/clinical tools,
diagnostic, instrument disposable, implantable, etc.), development history (new, second,
third or later generation device), and time since market release. Respondents were also
asked to indicate the degree of change made to the device as a result of RM activities and
to rate the effectiveness of associated RM activities for the device. Survey results
indicated that RM’s impact and level of effectiveness on a medical device are dependent
primarily on the device type and life-cycle stage (i.e., pre-market versus post-market).
There is also some impact of development history and the time since the device was
released to market.
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Introduction
The extensive innovations in medical device technology have supported the
increasing demands of the health care industry over the past twenty years (Foote, 1988).
Even in a highly technology-driven environment, it is still crucial that products are
designed and developed to meet requirements of relevant International Organization for
Standardization (ISO) standards and Food and Drug Administration (FDA) regulations
that assure quality and safety.
Product liability and regulation have increasingly become major issues for the
medical devices industry (Foote, 1988). For this reason, medical device manufacturers
and the FDA face the challenging role of ensuring a stringent process is in place for
medical device risk assessment. But with all the standards and regulations imposed for
the assurance of a medical device’s effectiveness and safety, the amount of risk involved
is still in question on devices that are approved for market release (Dyadem International,
2008). A 100% risk-free device is never attainable (T. Chan, personal communication)
but a systematic assessment of potential risks associated with a medical device can
significantly reduce potential harm to the user, manufacturer, and the medical device
industry in general.
This study focused on the implementation of selected risk-analysis activities and
techniques over the life cycle of a medical device. This study studied its impact for an
effective risk management, that, when effectively carried out, will help to significantly
reduce product returns and litigations. The risk analysis techniques include Risk
Acceptance Criteria, Hazard Identification/Preliminary Hazard Analysis (PHA), Human
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Factors/Usability Analysis/Use Failure Mode and Effects Analysis (FMEA), Design
FMEA, Process FMEA, Hazard Operability Study (HAZOP), Hazard Analysis and
Critical Control Point (HACCP), Risk Benefit Analysis, and Risk Assessment of
Customer Complaint. The use of these techniques was evaluated in the different phases
of the design life cycle, which includes conceptualization, initial development, design
verification and engineering validation, design transfer, clinical validation, pilot
production, manufacturing scale up, production monitoring and reporting, and field
production monitoring and reporting.
Statement of the Problem
Litigation and product recalls are still predominant in a heavily regulated industry
such as the medical device industry (e.g., Medtronic pacemakers, Baxter pumps, Guidant
defibrillator and pacemakers). Medical device manufacturers must be able to select the
risk management activities that are suitable for their type of product, and employ them at
phases where they are most appropriate and effective. This provides industry
professionals with a basis for identification of potential hazards and means to effectively
address the risks involved. The problem is to understand how risk management activities
currently influence the development of a medical device.
Research Questions
Do regulated risk management activities play a significant role in the medical device
product development?
What is the level of effectiveness of risk management activities in the medical device
industry?
2

Hypotheses
H1: Risk management activities drive the changes in the development of a medical
device.
H0: Risk management activities do not have any impact in the development of a
medical device.
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Review of the Literature
History of Risk Management
With no formal regulation to oversee RM, recognition of ISO 14971 and GHTF
guidance came about in the late 20th century to help medical device manufacturers
manage the risk associated with their medical device. The flowchart in Figure 1 depicts
the evolution of risk management and the associated standards and guidance that support
the framework of systematically applying risk management activities within the device
life cycle process.
Risk Assessment Requirements and Management
It is critically important that medical device manufacturers do not only implement
a full risk assessment process of a medical device but also ensure that a solid risk
management is also implemented (Medical Device School, 2005). This way, the
potential risk of a product can be readily addressed from the time it was being
conceptualized to the moment when it is released and disposed. The many regulations
and standards pertaining to risk management in medical devices, and the establishment of
the Global Harmonization Task Force (GHTF) whose mission is to harmonize these
regulations and standards globally, will ease the implementation of the risk management
process (Global Harmonization Task Force [GHTF], 2009). GHTF includes Australia,
Canada, European Union, Japan, and the United States (World Health Organization
[WHO], 2003).
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GHTF Guidance: 1992
(inception)

Identify hazards
including IVD
Estimate/Evaluate
associated risk
Control risk
Monitor
effectiveness of
controls

Harmonize regulations and
standards globally to ease
the implementation of risk
management process.

Figure 1: Evolution of RM (G. Rao, personal communication, September 29, 2010)
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The international standard for risk management of medical devices is ISO14971.
The standard covers the risk determination and application activities for the whole life
cycle of a medical device from design, development, and manufacturing (International
Organization for Standardization [ISO], 2007). The risk process determination stated in
ISO 14971 has two important steps such as the collection and dissemination of
information. The collection process engages in quality planning that covers the
development of risk management plan, identification of potential hazards, estimation, and
validation of risk. This information is then disseminated back through design input,
design output, and design verification. Risk analysis (hazard identification), risk
evaluation (risk acceptability), risk control, and risk monitoring (post market
surveillance) are the critical parts of a medical device risk management (Medical Device
School,
2005). It is also good to take into account that risk analysis and risk evaluation must be
applied in all phases of the product life cycle (Emergo Group, 2009).
Pre-market product control. Pre-market handles the product’s adherence to
government regulations and thus falls within the scope of risk management. Different
countries have different rules and standards for their product’s approval, however it is the
same risk management philosophy that governs these requirements, and that is to ensure
device’s safety and performance (WHO, 2003).
According to WHO (2003), the higher the complexity of the design, the higher the
risk of user error. It is important that unwarranted risks are avoided at the design and
conceptualization stage through adequate test validation, verification, and clinical trials.
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Manufacturers are also responsible for ensuring that products meet the requirements and
design specifications. This is done through good manufacturing management that
implements the quality system regulations (GHTF, 2009). Good manufacturing practices
(GMP) describe the quality system for FDA-regulated medical devices that includes
process validation and design controls. These requirements are covered under 21 CFR
Part 820 of the GMP regulations. FDA (1987) requires manufacturers to establish
regulations applicable to their products’ functions, as GMP regulations are broad and
cover the general product market. It is the manufacturer’s responsibility to follow the
procedures suitable to the product being manufactured. GMP also needs to be consistent
with the requirements set in ISO: 9001 “Quality Systems – Model for Quality Assurance
in Design, Development, Production, Installation and Servicing” and ISO 13485 “Quality
Systems – Medical Devices – Supplementary Requirements to ISO 9001 (FDA, 1987).
Also included in the pre-market control of a medical device are packaging and
labeling. Manufacturers must ensure that safe handling of the device is observed at all
times to avoid accidental tampering of information on the labels. The package must be
well sealed with hazard warnings and clear instructions (WHO, 2003).
Placing on-market. This stage of the life span of a medical device is the
responsibility of the vendor. Advertisements are powerful means to convince the users of
the device’s capabilities to meet their expectations. Thus, marketing of products must
also be regulated to avoid mishandling when products are put into their intended use
(WHO, 2003).
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Post-market surveillance. User error is considered the most common cause of
death or injury related to medical devices, according to WHO (2003). It is stated in ISO
13485 and FDA that companies must have processes in place to obtain customer
feedback for trend monitoring and data review (Emergo Group, 2009). It is also noted
that for the process to be effective, a regular review meeting must be held so that updates
are disseminated and corrective and preventive actions (CAPA) are implemented when
necessary. Data may also include product and process non-conformances, complaints,
and customer survey. According to ISO 14971, post market surveillance should include
the following (Emergo Group, 2009):
Systematic process for product evaluation including customer complaints.
New hazard evaluation.
Objective evidence contained in the file for risk management.
Determination of changes, if any, in the acceptance of the original risk.
Revisions and feedback to the risk assessment and management as required.
In addition to monitoring the products risk it is important to note that a proof of
documentation that shows how the data are analyzed, inspected, and studied must be
readily on hand. It must also include information on who performs the investigation and
how many times this process is performed. It is important that the medical devices
industry has this on-going process for post surveillance trending and reporting of the
product’s condition to reaffirm its safety and be able to act suitably on any adverse
effects that they may inflict on the user (Rodriguez, 2009).
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Figure 2 (WHO, 2003) shows the life span of a medical device from conception to
disposal. It also depicts the party responsible for ensuring that regulations are addressed
appropriately to reduce, if not eliminate, potential risk through proper monitoring of the
safety and performance of the device even after sale. An effective risk management
emphasizes the different assignments for the responsible people in each stage of the life
cycle. WHO (2003) also noted that product and use are the two critical elements that
guarantee the safety and performance of a medical device. Pre-market review governs
product control while the post market surveillance ensures its use to be continuously safe
and effective. The placing on-market process in between which includes packaging,
labeling, advertising and sale avoids misrepresentation. It is responsible to let the user
know the device’s intended use.

Figure 2: Stages of a medical device life span (WHO, 2003)
The regulatory framework in Table 1 summarizes the most common activities that
require regulations in medical device. The different stages were tabulated with
identification of the person in charge for controlling and monitoring the device, sale, after
sale, and use.
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Table 1: Common regulatory framework for medical device (WHO, 2003)
Stage
Control/Monitor
Person
Items or Activities
Regulated

Pre-Market
Product
Manufacturer
Device Attributes
- Safety and
performance
Manufacturing
- Quality systems

-

Placing On-Market
Sale
Vendor
Establishment
Registration
- List products
available or in use.
- Requires vendor to
fulfill after-sale
obligations.

Labeling
(representation)
Accurate
description of
product.
Instructions for use.

Post-Market
After-Sale/Use
Vendor/User
Surveillance/Vigilance
- After-sale
obligations.
- Monitoring of
device’s clinical
performance.
- Problem
identification and
alerts.

Advertising
(representation)
- Prohibits misleading
or fraudulent
advertisement.

Product Development Process
The product development process of a medical device ensures that the device
delivered to the customer has gone through rigorous steps to guarantee quality, safety and
reliability. It is important that product requirements are clear so that design controls are
defined and established. Design control as described by Gopalaswamy & Justiniano
(2003) is “a set of disciplines, practices, and procedures incorporated into the design and
development process of medical devices and their associated manufacturing processes”.
Discipline is what administers the performance of the design activities to be able to
practice them as appropriate. The procedures, on the other hand, are the step-by-step
guidelines that are followed accordingly. These set of controls, as well as the design
inputs, are then converted into System Requirements Specifications (SRS), which are
documented and maintained in the Design History File (DHF), together with the other
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important processes. Production of the device comes forth when the final product and
process specifications are completed and verified in conformance with the design
controls and SRS. Risk management is performed alongside the design and development
process to guarantee that the device being produced does not impose hazards onto the
user (Gopalaswamy & Justiniano, 2003).
Product requirements. The concept and development phase of product
development contains the product requirements. Product requirements define the
product’s intended use and the target users. The requirements should also cover the
following: device characteristics, quality and regulatory requirements, manufacturability,
human factors, reliability, labeling, packaging, and all the other pertinent information that
the designers find necessary to start the project. Information is obtainable from different
sources like interviews, research studies, past records or device history, and regulatory
requirements (Fries & King, 2009).
Design and development planning. Design and development planning includes
program goals and the design and development elements. The plan details the ways to
strategically align the team and the resources in terms of the needs defined by the product
requirements. The plan contains the schedule of how each action item should be
executed to meet the requirements. The plan is properly documented in the DHF. It has
to be regularly updated so that every member of the team is attuned to the changes made
until implementation is performed. Goals and objectives must also be clearly defined. It
is usually the Program Manager’s job to define the objective and to make sure that the
plan is executed as defined, and that the scope, size, and complexity of the development
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project are accurately addressed and understood. Revisions are signed and approved, and
recorded for proper tracking (Fries & King, 2009).
Design and Development Elements
Design inputs. The needs and requirements of the users are converted into
practical and technical design inputs.
Design activities. Refer to all activities that are performed in the product
development. May involve activities related to suppliers and contractors, or activities
that involve contingencies.
Design outputs. Determines activities to be developed for the desired design
output. Accuracy and reliability must be defined with tolerance limits. Design outputs
must also address quality, safety, and other factors as appropriate that are defined by
design and risk analysis.
Formal design reviews. Identify the timing, content and reviewers for a formal
design review. Every product must have at least one formal review to assess, at the very
least, the completed design inputs, outputs, and design validation. Design reviews should
also cover design issues and resolutions.
Design verification and test methods. Provides evidence that the required
development activities have been met and that the design outputs meets the design inputs.
Statistical techniques are employed at this stage. Includes integration testing, functional
testing, and biocompatibility. Data analysis should cover design tolerance, worst-case
scenarios, thermal analysis, as well as the outputs of risk analysis techniques like FMEA
and FTA.
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Design verification report. Contains the summary of design verification
activities, device history file, and all issues that were identified and resolved.
Design validation. Provides validation activities on the project development
activities performed like validation of test plans, test methods, software validation, risk
analysis, validation of labeling and packaging, reporting, and reviewing. User’s needs
and the device’s intended use are also part of design validation activities. The purpose is
to determine discrepancies that may result between production and manufacturing units
when operated in a simulated condition. Records and results of these activities are
contained in the design validation report, which also includes information on the methods
used and identification of the individuals who performed the validation. All these and
other references reside in the device history file.
Design transfer. Design is transferred to manufacturing, service, production, or
site location.
Design change control. Covers the criteria and responsibilities when approving a
design change.
Device history file (DHF). This is where all program project records reside to
provide ease of accessibility for everyone in the team. It contains previous DHF,
revisions, and updates.
Risk management. Includes activities for risk management that involves hazard
identification and detection of the degree of risk to the users.
System requirement specification (SRS). Details of the product design are
translated into system requirement specifications, which also include inputs from the
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activities performed in risk management. SRS requirements include (1) functional
requirements that define the operational capabilities of the device, (2) physical and
performance requirements that measure how well the device performs in terms of speed,
strength, and reliability, (3) interface requirements define the criticality and compatibility
of the device to its external interface, which includes the users, (4) system architecture
denotes relationships of the various systems and their requirements, and if applicable, (5)
software requirements for the product’s functionality that will need to be implemented
through software. SRS must also include the following as appropriate: toxicity, risk
management, biocompatibility, EMC, human factors, etc.
Risk Assessment Process
There are four integral steps in the risk assessment process. They are hazard
identification, dose-response assessment, exposure assessment, and risk characterization
(Cammack, Eyre, White &Wilson, 1999).
Hazard identification. Hazard identification is the process that involves the
determination of any adverse health condition upon exposure to an agent (e.g. chemicals).
Birth defects, cancer, decreased fertility, and thyroid dysfunction are just few of the cited
effects of one’s exposure to toxicants (EM-Com, n.d.). Hazards may be identified using
one of the following methods: (1) Epidemiological investigation, a study of the frequency
and distribution of diseases within human population. It has the advantage of knowing
and measuring the risk hazards that have direct effects on human (Daniels, Flanders &
Greenberg, 2005). (2) Toxicological studies. It is a method of measuring health hazards
affecting living organism. It is usually conducted in a controlled environment like the
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laboratory. Animals are used for conducting the test (EM-Com, n.d.). (3) Ecological
studies. This is a method of determining hazards based on the ecological studies of
wildlife. It is believed that potential endocrine disrupters that have adverse affect on
animals may be potentially harmful to human as well (EM-Com, n.d.).
Dose-response assessment. “All substances are poisons: there is none which is
not a poison. The right dose differentiates a poison and a remedy. Paracelsus (14931541)” (EM-Com, n.d.). The characterization of dose-response relationship involves
determination of the amount of agent that will not cause an effect. This is the
determination of the upper limit, which is also called as the “allowable limit” (Gad &
McCord, 2008). The response to the agent varies depending on the level of exposure,
duration of contact or the agent’s level of toxicity (Cammack et al., 1999).
Exposure assessment. This is the estimation of the quantifiable dose of human
exposure to an existing agent. Estimation includes that of the duration, frequency, and
intensity of exposure (Gad & McCord, 2008). One’s exposure to different toxicants may
come from the different sources in the environment, which may be synthetic or natural
occurring. Synthetic sources of endocrine toxicants can be categorized as voluntary or
involuntary exposure. The former includes exposure to commercial products like
pesticides, cosmetics or medications. The latter may come from contamination in water,
air or contact in the contaminated soil (EM-Com, n.d.).
Routes of exposure in the human body differ according to the chemical properties
and human biology. Routes of exposure can be dermal (skin-absorbed), respiratory
(inhaled), and gastrointestinal (ingested). Chemical toxicants that are insoluble in water
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like PCB’s can be skin absorbed while chemicals that are volatile can be inhaled. Once
contaminants enter the body, they travel to organs and tissues through bloodstream. The
measure of exposure to chemical contaminants in the body is done through blood
sampling (EM-Com, n.d.).
Risk characterization. The final step of the risk assessment process includes the
evaluations and results of the previous three steps. Risk characterization measures the
overall risk of the agent towards human exposure. The allowable limit is then compared
to the estimated limit of adverse health effects that determines the agent’s safety (Gad &
McCord, 2008).
Risk estimation is assessed in direct proportion for both levels of hazard and
exposure. The presence of both assessments constitutes an end result that determines the
amount of risk involved. If a hazard exists and the risk is known to be low, then it is an
acceptable risk. In the context of the total risk assessment, the uncertainty of the hazard
level is a pre-defined approach for a more extensive analysis on the amount of hazard
involved in the compound (Gad & Jayjock, 1988).
The four risk assessment steps discussed are vital to the overall assessment of the
medical device’s exposure to risk. Thus, it is important to take into consideration the
accuracy of the test data and results that will determine the device’s acceptable safety
level for market release.
Medical Device Classification
Part 860 is the medical device classification procedures defined by the Food and
Drug Administration (2004). Medical devices are classified according to the potential
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risk that they may impose on the user and are based on FDA’s level of regulatory control
to release and market the device. The higher the class, the higher is the risk and the
higher is the number of regulatory controls.
Class I devices are considered the lowest risk devices as their design is not
complicated; they are simple to manufacture and safe to users. These devices do not have
histories of possible damages and are only subject to general controls. They also do not
usually require pre market notification, as general controls are sufficient enough to
guarantee their safety and effectiveness. FDA (2004) defines general controls as the
inclusion of the following: “section 501 (adulteration), 502 (misbranding), 510
(registration), 516 (banned devices), 518 (notification and other remedies), 519 (records
and reports), and 520 (general provisions) of the federal food, drug, and cosmetic act”.
Devices like handheld surgical instruments are considered Class I, as they are not life
supporting devices (LEEDer Group, 2009).
Class II requires general controls and special controls. Devices under Class II are
riskier than Class I and may be used for supporting human life. Thus, FDA (2004)
requires manufacturers to fulfill sufficient evidence that these devices are assured to be
safe and effective by establishing the following: proliferation of performance standards,
post market surveillance, patient registries, development, and distribution of guidance
documents that include pre market notification according to 510(K) act for market
submission. More actions and evidence may be requested by the Commissioner should
the manufacturer fail to build strong proof that the device is safe for use. Examples of
Class II devices are x ray, pumps, and surgical drapes (LEEDer Group, 2009).
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Class III devices are the riskiest among the classes of medical device as these
devices are used for sustaining human life. Examples are replacement heart valves and
silicone gel-filled breast implants. Devices under this category are usually required to
have both a Pre-Market Approval (PMA) and 510(K) clearance for market submission
(FDA, 2004). The Commissioner may also require additional evidence of safety and
effectiveness when deemed necessary.
United States Regulatory Pathway
Regulatory requirements for clinical trials. The International Review Board
(IRB) is defined as “…any board, committee, or other group formally designated by an
institution to review, to approve the initiation of, and to conduct periodic review of,
biomedical research involving human subjects. The primary purpose of such review is to
assure the protection of the rights and welfare of human subjects” (Segal, 1998). IRB
ensures that the rights of the subject matter are protected and that their risk to potential
hazards is minimized. IRB also has the authority to grant approval or disapproval, to
continue or discontinue a clinical trial. All clinical trials must be conducted according to
the Investigational Device Exemption (IDE) regulations. Devices exempted from IDE
regulations include pre amendment and SE devices, with provisions that they are not
transitional devices and were investigated according to the labeling that was FDA
reviewed at that time. An IDE application that was approved by FDA is required prior to
a clinical trial on a device that has a significant risk. All approved clinical trials must be
performed in accordance with the Good Clinical Practices (GCP). GCP refers to the
approved standards and federal regulations relating to clinical studies that include
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reporting and record keeping requirements, gathering of scientific data, subject’s
informed consent, and data that contains safety and effectiveness information required by
the regulatory bodies. A standardized GCP called Guideline on Good Clinical Practice
was formed by the International Conference on Harmonization of Technical
Requirements for Registration of Pharmaceuticals for Human Use to have a standardized
set of guidelines for the U.S., European Union, Japan, Australia, Canada, the Nordic
countries and WHO (Segal, 1998).
Significant risk (SR) and non significant risk (NSR) device. SR device is
defined as “…an investigational device that presents a potential for serious risk to the
health, safety, or welfare of a subject and is an implant; or is used in supporting or
sustaining human life; or is of substantial importance in diagnosing, curing, mitigating
or treating disease, or otherwise prevents impairment of human health; or otherwise
presents a potential for serious risk to the health, safety, or welfare of a subject” (Segal,
1998). An NSR device, on the other hand, is one that does not meet the description of an
SR device. Appendix A shows a list of examples of SR and NSR devices taken from the
Center for Devices and Radiological Health (CDRH) (2006). Sponsors and IRB use this
list in reference to their determination whether a device is SR or NSR. It is noted though
that the list under NSR devices may not be considered final because the risk evaluation
must determine the intended use of the device in a study.
The IRB reviews the sponsor’s proposal for a clinical investigation based on the
device description, investigation plan, reports of past investigations related to the device,
and the criteria for subject selection. It is the IRB’s discretion to classify whether a

19

device is SR or NSR. In this regard, FDA considers that IRB has the standard operating
procedures (SOP) to conduct the clinical reviews on the subjects being studied for
diagnostic or treatment purposes. Data confidentiality, impartial subject selection, a
documented consent, and sufficient provisions that define the subject’s protection of
privacy are some of IRB’s conditions for a clinical trial review. Any risks that may be
imposed on the subject matter must be proven reasonable for the intention of the benefits
and knowledge that are achieved at the end of the investigation. Thus, SR and NSR
determination is based on the potential harm that may be inflicted on the subject
participating in the investigation, plus the harm it entails in the use of the device, whereas
IRB’s approval for implementation of the clinical trial is based on the study’s risk-benefit
assessment (CDRH, 2006).
SR device studies should conform to the regulations set by IDE at 21 CFR 812
and an approved application from FDA before commencement. While NSR device
studies has the abbreviated requirements at 21 CFR 812(b) for compliance (CDRH,
2006). Food and Drug Administration (FDA) Reviewing Process.
The FDA’s role is to ensure that products released to market have sufficient
evidence of safety (potential risk) and effectiveness (intended use) through clinical
investigations conducted in accordance with the rules and regulations of the
administration. Appendix B shows the scope of the review type and requirements
according to the level of submission.
Pre-market review. In May 1976, Congress issued the Medical Device
Amendments requiring FDA to have all Class III medical devices to go through the PMA
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process before they can be commercially released. Devices released before May 1976
were classified as pre amendment devices while those marketed after were categorized as
post amendment devices (“Medical Devices: FDA,” 2009). PMA review is conducted for
post amendment devices that are deemed non substantially equivalent (NSE) to a pre
amendment device and should submit adequate clinical investigations for the products
release. Either that, or the Class III device will have to be reclassified as Class I or II.
Substantially equivalent (SE) devices, on the other hand, that have the same intended use
as the predicate device (pre amendment devices with approved 510(K)) with the same
technological characteristic (TC), or with different TC but proved to be safe and effective
as the predicate device, can submit a 510(K) clearance to market (“Medical Devices:
FDA,” 2009). A less stringent 510(K) submission is seen to be dominantly favored than
PMA by most medical device suppliers for grounds of faster turnaround time and
enormous savings in cost. Moreover, 510(K) submissions only include comparative
descriptions that includes performance data, and is more focused on the end product than
the manufacturing process itself (“Medical Devices: FDA,” 2009). Table 2 shows
GAO’s (2009) findings of FDA’s approved devices based on 510(K) and PMA
submissions comparing turnaround time and cost.
Post-market surveillance. FDA’s post market surveillance guarantees that
devices remain safe and effective after they are released to the market through the
analysis of the annual reports that were submitted to them by users and manufacturers.
Reports include serious device related injuries, device malfunctions, and death (“Medical
Devices: Shortcoming,” 2009).
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FDA agents are responsible for the research and investigation of issue trends in
relation to the medical device safety, while FDA scientists are in charge for the review
and follow up investigations based on the initial reports received. FDA scientists will
issue necessary steps and actions for issue resolution and they can also issue product
recalls, advisories or even require the manufacturers to change instructions in their device
labeling as necessary (“Medical Devices: Shortcoming,” 2009).
Table 2: 510(K) and PMA Submission Comparison (“Medical Devices: FDA,” 2009)
Turnaround time
(based on 2009 data)
510(K)
Submission
PMA
Submission

90% within 90 days

Cost
FDA reviewing
Applicant submission
submission (FY 2005)
(FY 2009)
$ 18, 200
$ 3,693

98% within 150 days
60% in 180 days
90% in 295 days

$ 870,000

$ 200,725

Inspection of manufacturing establishments. For both pre market and post
market supervision of medical devices, FDA also takes responsibility in making sure that
the manufacturing establishments strictly follow the standard manufacturing requirements
for device safety and effectiveness, and that local and international requirements are
properly accounted for. It is also required that they inspect Class II and III device
manufacturing establishments every two years (“Medical Devices: Shortcoming,” 2009).
The provisions included in Congress’ Medical Device User Free and
Modernization Act of 2002 (MDUFMA) was instituted to support and increase the
number of manufacturing establishments that are FDA inspected and to help
manufacturers perform a single inspection that will cover both local and international
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requirements. In response to these provisions, FDA formed the Accredited Persons
Inspection Program and the Pilot Multi-purpose Audit Program (with Health Canada) that
will allow manufacturers to acquire inspection services that will ease their compliance to
the governing requirements in the US and abroad, as well as reduce the cost that would
have been incurred if it were done in multiple inspections. (“Medical Devices:
Shortcoming,” 2009).
Risk Analysis Techniques
Risk analysis is a fundamental requirement in the submission checklist for PMA
and 510(K) and a significant guideline contained in GMP. The hazardous effects of a
device are of great consideration before a product is approved for market release. Thus,
the law requires the inclusion of risk analysis in the design phase of a medical device for
early detection of adverse events that can cause serious harm to the user (Kamm, 2005).
Systematic methods for identifying and measuring the potential risk or hazard are
specified in Annex G.6 of ISO 14971. These tools are used to effectively carry out the
risk analysis of a medical device. Utilization of more than one tool may be necessary on
an event that requires it (ISO, 2007).
Preliminary Hazard Analysis (PHA). PHA is a method of identifying potential
hazards at the very early stage of design where a more extensive approach may not be
suitable. It is importantly useful in the analysis of systems where preliminary design is
underway as it identifies the harmful effects caused by an event or a situation. This helps
lead the designers to take the steps necessary to alleviate the system’s or activity’s
potential risk. Other names that are associated to PHA are Rapid Risk Ranking and
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Hazard Identification (HAZID) (Rausand, 2005). PHA risk analysis takes the following
characteristics into consideration: system interfaces, equipment used, environmental
constraints, layout, and hazardous components (ISO, 2007). A typical PHA worksheet is
shown in Appendix C.
The PHA risk analysis process can be broken down into four steps: (1)
Establishment of PHA requirements, (2) Identification of potential hazard, (3)
Measurement of frequency of occurrence and its severity, and (4) Risk ranking (Rausand,
2005).
Establishment of PHA requirements. PHA involves formation of the analysis
team. This team should be able to clearly define and describe the potential problem
according to system, equipment, environment, layout, and components involved and the
subject being analyzed. The team must document the measures for detection and
prevention for the establishment of design controls. Supporting data taken from past
cases with related events are also good sources for investigation.
Identification of potential hazard. Every factor that is likely to cause danger
must be identified. The list can go from maintenance operations to system safety, etc.
Measurement of frequency of occurrence and its severity. Events are ranked
based on the severity of the failure outcome and the frequency of this outcome.
Risk ranking. Three categories (critical, major, minor) define the severity of
failure in the PHA matrix and they are tabulated against the estimated frequency of
occurrence. Recommended actions are based on the acceptability level.
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The “as low as reasonably practicable” (ALARP) principle is the action
determined for fairly acceptable cases. These are considered low-level risks that do not
need further actions. The medium level acceptable situations will require further
investigations and verification of the effectiveness of the corrective actions. A
reassessment of the risk score may be required to verify improvements. The high-level or
unacceptable risks take on the more rigorous actions to address the potential hazards
involved. Verification of corrective actions is a requirement for risk reassessment.
The PHA process of risk analysis supports design resources like time and cost as
it helps to ensure that potential risks are identified at the earliest time possible. However,
it is also a challenge for designers to execute the plan of performing PHA as hazard
interactions may not be easily recognizable and potential hazards may not always be
foreseeable (Rausand, 2005).
Usability Engineering/Human Factors. Usability Engineering or Human
Factors is a process of designing a device with high consideration on human accessibility
and compatibility. Meeting the needs of the users and at the same time taking into
account the standards and regulations that govern design implementation. Many
companies now employ usability engineering into the product life cycle as it covers a
systematic approach to design techniques and vast information on human characteristics.
Greater customer satisfaction is also highly anticipated by companies that employ this
technique. Users play a significant role through interview, user feedback and survey
(Wiklund, 1995).
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User studies. Most medical device manufacturers employ focus groups that study
the type of users of the device. They are formed to study the needs of the users, how they
will use the device, and how often the users will use the device. Interviews and survey
questionnaires are often employed by the focus groups to obtain answers to these
questions that will significantly help in getting the usability testing started.
Usability goal setting. This is the step wherein usability goals are defined and
then compared to the design goals set. It usually involves a team of people who makes
the realistic assessment of obtaining usability goals that will fit the design and vice versa.
Concept development. This step includes exploration of mental concepts,
establishment of a user interface structure, concept modeling, and evaluation.
Detailed design. A realistic design is developed in this stage. All things
considered such as usability test results, modeling, and evaluation.
Specification. Proper documentation of instructions and manuals is addressed in
this step. Include drawings, reports and user interface descriptions.
Field activities. The practical use of the actual device is evaluated and user
feedback is obtained. According to studies, most nurses make usability a requirement
before actually using a device.
Though the usability test can be planned and performed in the various phases of
the device life cycle, it is most effectively conducted when a device is ready to market
and has proven reliable in meeting the customer’s needs. A prototype of the actual
device is more appropriately suitable to perform the test to get accurate information on
the user’s perspective on the device’s ease of use and compatibility. Test plan should
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include the objective, type of data to be collected, number, and type of test subjects, and
upon completing these steps, the documented analysis of test results. Test objectives may
contain collection of user’s inputs on device improvement, determination of the device
more preferred by the user and development of baseline upon user performance. Baseline
considers incident and success rate and completion time. The place where the design
must be conducted must also be defined be it in an office environment or a laboratory set
up. Data analysis may employ statistical tools that can effectively separate the problems
from successes like comparison of the mean and standard deviation. The use of statistical
analysis makes it easier to convey the necessary information. Finally, usability report
must cover a summary of the test results and recommendations for design improvement
when appropriate (Wiklund, 1995).
Fault Tree Analysis (FTA). FTA is a top down approach of problem solving
(O’Connor, 2002). It starts with identifying the potential hazard and breaks it down to
failure modes that may have caused the hazard. This approach uses logic gates like “and”
and “or” gates to relate potential failures to possible causes. It provides a systematic
approach to problem solving as it visually details the causes and effects of activities or
human related factors that may have caused a high level of risk if overlooked (Kamm,
2005). The tree like representation of root cause analysis gives the reviewer a clear
picture, at a glance, of each of the possible scenarios that is taken into consideration. For
large complex systems where failure modes may be enormous, software programs are
now available to aid organizations in doing FTA (O’Connor, 2002).
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FTA steps include the list of possible hazards like injury, electric shocks, and fire,
and the identification of failures and failure modes that may have resulted in these
hazards. Construction of a fault tree diagram may begin with these lists, and elimination
of unacceptable events may then be carried out.
Failure Mode and Effects Analysis (FMEA)/Failure Mode, Effects, and
Criticality Analysis (FMECA). Contrary to FTA, FMEA uses a bottom up approach of
problem solving. It is performed in the early stage of design development, usually at the
feasibility stage, to assess every component’s possible risk (Bhote & Bhote, 2004). A
component level assessment gives designers ideas on what they can improve in the
design to improve the product’s reliability and make it less susceptible to harmful
failures. The failure modes and their severity are assessed based on risk index that will
also determine the necessary actions for improvement, and this is where the term
FMECA comes into play (Kamm, 2005). The two types of FMEA are Design FMEA
(DFMEA) and process FMEA (PFMEA). DFMEA deals with design inadequacies and
their effect on manufacturing operations, while PFMEA assesses the potential risks that
may possibly transpire in the plant. While these two types have various potential
problems that are different from each other, the FMEA approach is still similar, and takes
into account the early signs of failure to avoid further changes on the later part of the
design or process (Kamm, 2005). FMEA process steps include definition of the system
being analyzed, identification of the failure modes and their effects associated with the
system or component being investigated, measurement of risk index, and determination
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of corrective and preventive actions for improvement. Implementation of these actions
must be monitored to ensure that desired output is met (Kamm, 2005).
FMEA uses risk index to determine the severity of the failure. It is calculated
based on the probability of occurrence versus the severity. The final score will reveal the
acceptability criteria most suitable to the level of hazard of the failure mode (Kamm,
2005). Safety precautions that are significantly beneficial to using the FMEA in
preliminary design include the use of sound judgment of the designer to only include the
most unreliable parts and their potential failures. The attention is focused on the
corrective actions that contribute most significantly in determining the part’s reliability
(Bhote & Bhote, 2004)
Hazard and Operability Study (HAZOP). HAZOP is a team approach problem
solving method. It involves people with different expertise whose conviction of the
process or system that is analyzed is what makes the HAZOP analysis effective and
easily carried out.
The purpose is to identify the potential hazards that can come out of the system in
review, and to be able to identify the methods and actions necessary to minimize the
hazards (ISO, 2007). Guide words like “no/not, more, less, as well as, part of, reverse
and other than” help to describe the failure or design deviation (O’Connor, 2002). The
objectives of HAZOP analysis are to provide a full description of the medical device and
its intended use, to review each of the intended use and determine how design deviations
can possibly occur in each of the intended use. It is important to know the consequences
of these deviations that can lead to possible hazards (ISO, 2007).

29

Hazard Analysis and Critical Control Point (HACCP). HACCP is a
systematic approach for identifying, evaluating, controlling and monitoring of possible
hazards that take place in the different life cycles of a medical device. Life cycle stages
include design, manufacturing, service, use and disposal. HACCP is typically used in the
latter part of the design phase to optimize design changes (ISO, 2007). HACCP is an
approach that was first used by NASA to monitor food poisoning of the food being
supplied to their astronauts, and was later adapted by WHO to include in the risk analysis
methodology for drugs and pharmaceutical products (T. Chan, personal communication).
HACCP’s seven guiding principles as defined by ISO (2007) include: (1) Carry out a
hazard analysis and identify preventive measures, (2) Determine critical control points
(CCP’s), (3) Generate critical limits, (4) Create a system for CCP monitoring, (5)
Establish corrective actions for out of control CCP’s, (6) Generate procedures for
verification of HACCP effectiveness, and (7) Establish documentation and record
keeping. An effective HACCP system is governed by continuous controlling and
monitoring of the hazards identified (principles 2, 3 and 4), the manufacturer’s ability to
ensure that the system is in control and that corrective measures are effectively in place
(principles 5 and 6), and establishment of effective documentation that includes process
flowcharts, hazard analysis worksheet and HACCP plan. The process flowchart should
be able to clearly describe the process as it serves as a guide to the team who is reviewing
it. It is important that a step-by-step description of the process is stated for better
understanding of the methods incorporated within. The hazard analysis worksheet
contains the hazards that were identified in the process and their significance. A list of
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the control measures, including the CCP’s, is also visible in the analysis worksheet. The
HACCP plan is formulated based on the seven principles and ensures that proper control
is in place for the control and implementation of the procedures in relation to design,
products, processes or procedures (ISO, 2007). Benefits include great reduction of
customer complaints and product recalls, better time management as downtime is
reduced, and increase employee awareness of process controls with ownership of product
safety and effectiveness (T. Chan, personal communication).
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Methodology
The survey design was established through the help of an industry expert, Dr.
Geetha Rao, who also helped in the data analysis. Three medical device professionals
were selected to validate the survey design and do a trial run. The feedback gathered
from these 3 respondents helped to revise the survey with particular considerations on the
number of questions, the type of questions asked, the time allotment to complete the
survey, and the method to answer the survey.
Final revision of the survey is provided in Appendix D. This survey was posted
online using Survey Monkey. It was designed as a 10-minute online survey consisting of
22 questions. The questions were divided into three sections: introduction (about the
medical company), information on a selected medical device, and risk management
assessment.
The actual email that was used to invite medical device professionals to
participate in the survey is provided in Appendix E. This email, which also contains the
link to the survey was initially distributed privately in March 2010 to 20 individuals who
work at medical device companies or whose work is associated with medical devices.
Later the survey was distributed more broadly through ASQ-NCBDG (American Society
for Quality – Northern California Biomedical Discussion Group) out to its 400-member
mailing list.
Answers to the survey were gathered over a period of two months. There were a
total of 41 responses received over the total 3-month period. Sixteen of the respondents
completed the entire survey but of those only 14 responses were considered valid as 2 of
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the survey respondents either misunderstood a question or mistakenly answered a
question on the rate of the effectiveness of RM. One out of the 14 respondents did not
provide a clear definition of the medical type so only 13 medical device types were
identified.
Qualitative data analysis for this type of non-experimental design was utilized,
with supporting charts and tables to present the actual results gathered from the survey.
Analysis charts were created for the following:
The degree of change of the risk analysis technique used at every phase of the device
life cycle.
The effectiveness of the risk analysis technique used at each phase.
Data Analysis
With the different variables (development phase, RM activity, degree of change,
effectiveness) that are factored in, it was initially difficult to discern the significance of
each variable and come up with any immediate conclusion. Intermediate data analysis
was used as a part of the initial assessment for the varying results gathered from the
survey. The initial data analysis helped gauge whether the results that were collected
would be able to provide any justification to the hypotheses. The results indicated some
evidence to support the hypothesis that RM activities have an impact, but this was not
true across the board. More detailed analysis was performed to understand the impact
more granularly. The conclusions established from the survey results were done based on
the method described in the Final Data Analysis.
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Intermediate data analysis. Individual responses on risk management
assessment (degree of change and effectiveness) were tabulated against the RM activities
performed during each phase (see Appendices F1 to F9, and G1 to G9 for charts).
A numerical value was assigned to rate the effectiveness: 5 (high), 3 (medium),
and 1 (low). The scores on effectiveness were based on the number of times the RM
activity was used (implementation) at every phase, and the respondents’ individual rating
of its effectiveness (calculated). The scores provided an indication of how the different
techniques can contribute to a change in design, manufacturing, and labeling.
Implementation score is the frequency of use of the RM activity at each phase,
while effectiveness score was calculated by using the following formula: Sum of the rate
of effectiveness / Implementation score.
For example, in the Conceptualization phase, 4 medical device professionals are
using Hazard ID/PHA. The following ratings were obtained for the risk analysis
technique’s effectiveness in catching problems: two 5’s (high) and two 1’s (low). What
is the effectiveness score?
Implementation score = 4
Sum of the Rate of Effectiveness = 5 + 5 + 1 + 1 = 12
Effectiveness score = Sum of the rate of effectiveness / Implementation score
Effectiveness score = 12 / 4 = 3.0
Thus, the effectiveness score of the risk analysis technique, Hazard ID/PHA in
catching problems is 3 at the Conceptualization phase. A score of 3 means that Hazard
ID/PHA is moderately effective in catching problems at the Conceptualization phase.
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Final data analysis. A color coding scheme was used to distinguish the type of
change that happened over the device’s life cycle, as well as to rate the effectiveness of
the RM activities for the following factors: catching problems, early identification of
potential risk, identification of product improvements, saving cost, and overall design
quality. Figures 3 to 16 show the charts for the 14 individual responses.
Degree of change.

The number of labeling, design and manufacturing changes

were counted and tabulated for each of the development phase. Colors used for the type
of change are as follows: orange for labeling change, blue for design change, and brown
for changes in manufacturing. The number of times (Y-axis) the type of change occurs at
each phase tells us how much of the RM activities can contribute to these types of
changes in the medical device life cycle.
Effectiveness. Effectiveness was rated high (red), medium (yellow) or low
(green). The ratings were tabulated for each of the development phase, and put into a
chart incorporating the colors associated with the ratings. The colors indicate the effect
of the RM activities for the following factors: catching problems, early identification of
potential risk, identification of product improvements, saving cost, and overall design
quality.
This color coding scheme has helped to visualize a pattern on how effectiveness is
rated high on some or all of the factors during the early stages, and how the ratings are
shifted from high to low during the post-market stage. As the individual charts were laid
out, common trends were observed on the effectiveness ratings based on three factors:
medical device type, device development history and the time since the device was
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market released. This led to the conclusion that the effectiveness of RM activities is
significantly impacted by these three factors.
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Discussion
Survey Findings
See Appendix H1 to H11 for the complete survey findings and results. The
medical device industry is comprised of a wide range of functions that provides for the
many different needs of the consumer population. The survey results revealed a high
number of medical device manufacturers that comprised 73.7% of the total survey
respondents. Medical device marketers placed as the second highest with 39.5%. Other
groups of medical device professionals belong to component and service providers,
wherein service providers are either consultants or educators. The responses gathered
from the survey were able to create the necessary evidence that helps to validate our
claim that the selection of risk analysis techniques over the life cycle of a medical device
provides medical device manufacturers the needed confidence to effectively carry out a
successful risk management. The percentage of respondents that perform risk
management at their work place is 95%. The remaining 5% do not necessarily need to do
risk management, as they are involved with either a consulting firm or an educational
institution. This is, therefore, solid evidence that risk management is an activity
performed in the medical device industry.
ISO 14971 is the international standard for risk management in the medical device
industry. The standard provides a high level assessment of identifying, controlling,
assessing, and accepting risk. About 83% of the respondents use ISO 14971 (2000,
2007). ISO 13845, which is the international standard for medical device quality system
regulation, is as well observed to a great extent, with 84% of the respondents claiming
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they are compliant. ICH Q9 compliant is 9.7%. One of the observations noted was how
some respondents may have confused standards from guidance documents as revealed in
survey question number 5, where others regarded ISO 14971 and ISO 13485 as guidance
documents instead of standards. Industry awareness of standards therefore, needs to
improve.
Survey results show 46% of the total population, operate with more than 5
product lines. While 33% have 2 to 5 product lines, and 7% with 1 product line. Other
survey respondents skipped this question.
The foremost important aspect of this study is to know how the different risk
management techniques affect the overall implementation of risk management
throughout the device’s life cycle. The degree of change and effectiveness brought about
by the RM techniques were evaluated. A closer look at these three factors: (1) medical
device type, (2) device development history, and (3) time since market release, have
shown significant impact on these factors, which have also made this study more
comprehensive.
Medical device types were divided into four categories: (1) surgical tools and
catheters, (2) diagnostic devices, (3) implantables, and (4) other therapeutic devices. A
total of 14 responses were analyzed based on the three significant factors mentioned, with
focus on the degree of change and rate of effectiveness. Here is the breakdown of the
medical device type of the 14 respondents:
4 Surgical tools and catheters
3 Diagnostic devices
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5 Implantable devices
1 Other therapeutic device
1 Unknown (respondent was not clear on the medical device type)
Twelve out of 14 have rated the effectiveness of the risk management techniques
used, while 13 were able to measure the degree of change. The preceding charts (Figures
3 to 16) show the individual assessments of the 14 survey respondents on the degree of
change and rate of effectiveness of RM in catching problems, early identification of
potential risk, identification of product improvements, saving cost, and overall design
quality. Table 3 is the summary of results and observations gathered based on the survey
response.
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Medical Device Type:
Surgical/Clinical Tools

Approximate Time Since Market Release:
6 months to 18 months

Device Development History:
Revision of previous first generation device

Figure 3: Degree of change and RM effectiveness assessment (Respondent no. 1)
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Medical Device Type:
Surgical/Clinical Tools

Approximate Time Since Market Release:
Unknown

Device Development History:
Unknown

(No response on the degree of change)

Figure 4: Degree of change and RM effectiveness assessment (Respondent no. 2)
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Medical Device Type:
Other (please specify) Catheters

Approximate Time Since Market Release:
18 to 36 months

Device Development History:
New, first generation device marketed for first time

Figure 5: Degree of change and RM effectiveness assessment (Respondent no. 3)
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Medical Device Type:
Surgical/Clinical Tools
Instrument Disposable

Approximate Time Since Market Release:
6 months to 18 months

Device Development History:
Revision of previous first generation device

Figure 6: Degree of change and RM effectiveness assessment (Respondent no. 4)
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Medical Device Type:
Diagnostic - Ophthalmic Imaging
Systems

Approximate Time Since Market Release:
6 months to 18 months

Device Development History:
Third or later generation device

Figure 7: Degree of change and RM effectiveness assessment (Respondent no. 5)
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Medical Device Type:
Surgical/Clinical Tools,
Diagnostic, Instrument Disposable

Approximate Time Since Market Release:
Greater than 3 years

Device Development History:
Revision of previous first generation
device

Figure 8: Degree of change and RM effectiveness assessment (Respondent no. 6)
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Medical Device Type:
Medical Device Type:
Diagnostic - hematology instruments
(blood cell counters)

Approximate Time Since Market Release:
Greater than 3 years

Device Development History:
Revision of previous first generation
device

Figure 9: Degree of change and RM effectiveness assessment (Respondent no. 7)
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Medical Device Type:
Therapeutic
Diagnostic
Implantable Electrophysiology at the San Jose
Campus

Approximate Time Since Market Release:
Greater than 3 years

Device Development History:
New, first generation device marketed for
first time

(Invalid response for effectiveness)

Figure 10: Degree of change and RM effectiveness assessment (Respondent no. 8)
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Medical Device Type:
Implantable

Approximate Time Since Market Release:
Not yet released – in clinical trial

Device Development History:
Third or later generation device

Figure 11: Degree of change and RM effectiveness assessment (Respondent no. 9)
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Medical Device Type:
Implantable

Approximate Time Since Market Release:
Not yet released – in clinical trial

Device Development History:
New, first generation device marketed
for first time

Figure 12: Degree of change and RM effectiveness assessment (Respondent no. 10)
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Medical Device Type:
Therapeutic, Implantable

Approximate Time Since Market Release:
Not yet released – in clinical trial

Device Development History:
New, first generation device marketed
for first time

Figure 13: Degree of change and RM effectiveness assessment (Respondent no. 11)
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Medical Device Type:
Implantable

Approximate Time Since Market Release:
Not yet released – in clinical trial

Device Development History:
New, first generation device marketed
for first time

Figure 14: Degree of change and RM effectiveness assessment (Respondent no. 12)
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Medical Device Type:
Therapeutic - investigational device
for migraine pain

Approximate Time Since Market Release:
Not yet released – in clinical trial

Device Development History:
New, first generation device marketed
for first time

Figure 15: Degree of change and RM effectiveness assessment (Respondent no. 13)
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Medical Device Type:
Therapeutic
Surgical/Clinical Tools
Diagnostic
Implantable

Approximate Time Since Market Release:
18 to 36 months

Device Development History:
Revision of previous first generation
device

(Invalid responses for effectiveness)

Figure 16: Degree of change and RM effectiveness assessment (Respondent no. 14)
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Table 3: Summary of the Effectiveness of RM activities by Respondent
Respondent

Device Type

No.

Development
History

Time since Market
Release

Summary of response

RM techniques used:
Establish risk acceptance criteria
Hazard ID/PHA
Human Factors/Usability
Analysis/Use FMEA
FTA
DFMEA
Risk Benefit Analysis
Risk Assessment of Complaint
Data/Customer Feedback
Degree of change
Design, manufacturing and
labeling changes during the premarket stage.
Effectiveness of RM
Rated high on all factors during
all pre-market stages.
RM techniques used:
Establish risk acceptance criteria
Hazard ID/PHA
Human Factors/Usability
Analysis/Use FMEA
Risk Benefit Analysis
Risk Assessment of Complaint

1

Surgical tool

Revision of previous
first generation device

Greater than 3 years

2

Surgical tool

Unknown

Unknown
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Data/Customer Feedback
Degree of change
(No response)

3

Other Catheters

New, first generation
18 to 36 months
device marketed for first
time

Effectiveness of RM
Cost savings was rated high at
the conceptualization stage.
Highly effective in catching
problems and identification of
product improvements during
field-production monitoring and
reporting.
(Not reliable data for techniques used)
RM techniques used:
Establish risk acceptance criteria
Hazard ID/PHA
Human Factors/Usability
Analysis/Use FMEA
FTA
DFMEA
PFMEA
HAZOP
HACCP
Risk Benefit Analysis
Risk Assessment of Complaint
Data/Customer Feedback
Degree of change:
More design changes at both
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pre-market and post-market
stages.
Design, manufacturing and
labeling changes at both premarket and post-market stages

4

Surgical tool

Revision of previous
first generation device

6 to 18 months

Effectiveness of RM:
Highly effective for all factors
(except for cost savings) at the
pre-market stage.
Cost savings and overall design
quality were rated highly
effective at the post-market
stage.
RM techniques used:
Establish risk acceptance criteria
Hazard ID/PHA
Human Factors/Usability
Analysis/Use FMEA
FTA
DFMEA
HACCP
Risk Benefit Analysis
Risk Assessment of Complaint
Data/Customer Feedback
Degree of change:
Design and labeling changes
during the early stages.
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5

Diagnostic
tool

Third or later generation 6 to 18 months
device

Effectiveness of RM:
Highly effective for all factors
(except for identification of
product improvements) at the
earlier stages.
Identification of product
improvements was rated high at
a later stage.
RM techniques used:
Establish risk acceptance criteria
Hazard ID/PHA
Human Factors/Usability
Analysis/Use FMEA
DFMEA
Risk Assessment of Complaint
Data/Customer Feedback
Degree of change:
Design and labeling changes at
V&V and post-market stage.
Effectiveness of RM:
Catching problems was rated
high at both pre- and postmarket stages.
Overall design quality is highly
effective at the pre-market stage.
Identification of product
improvements was rated high at
a later stage.
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6

Diagnostic
tool

Revision of previous
first generation device

Greater than 3 years

RM techniques used:
Establish risk acceptance criteria
Hazard ID/PHA
Human Factors/Usability
Analysis/Use FMEA
FTA
DFMEA
PFMEA
Risk Assessment of Complaint
Data/Customer Feedback
Degree of change:
Design changes at initial
development and V&V.
Manufacturing changes at a later
stage.

7

Diagnostic
tool

Revision of previous
first generation device

Greater than 3 years
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Effectiveness of RM:
Rated highly effective for all
factors in the earlier stages.
Effectiveness was not indicated
in the later stages, but it can be
inferred that RM techniques
were less effective during those
stages.
RM techniques used:
Establish risk acceptance criteria
Hazard ID/PHA
Human Factors/Usability
Analysis/Use FMEA

FTA
DFMEA
Risk Benefit Analysis
Risk Assessment of Complaint
Data/Customer Feedback
Degree of change:
Design, manufacturing and
labeling changes at the earlier
stages and at the production
monitoring & reporting stage

8

Implantable

New, first generation
device marketed for first
time

Greater than 3 years
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Effectiveness of RM:
Early identification of potential
risk, identification of product
improvements and overall design
quality were highly effective
during conceptualization.
All factors were highly effective
for all factors during initial
development.
Catching problems was rated
high during manufacturing scaleup. (No technique identified at
this stage but effectiveness was
indicated.)
RM techniques used:
Establish risk acceptance criteria
Hazard ID/PHA
Human Factors/Usability

Analysis/Use FMEA
FTA
DFMEA
PFMEA
HAZOP
HACCP
Risk Benefit Analysis
Risk Assessment of Complaint
Data/Customer Feedback
Degree of change:
Design was actually evolved.
Many later stage changes on
design, manufacturing and
labeling.

9

Implantable

Third or later generation Not yet released – in
device
clinical trial

Effectiveness of RM
(No response)
RM techniques used:
Establish risk acceptance criteria
Hazard ID/PHA
Human Factors/Usability
Analysis/Use FMEA
DFMEA
PFMEA
Risk Benefit Analysis
Degree of change:
Early design changes.
Manufacturing change during
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V&V.
Effectiveness of RM
Highly effective for all factors
during the earlier stages of the
pre-market phase.
10

Implantable

New, first generation
Not yet released – in
device marketed for first clinical trial
time

RM techniques used:
Establish risk acceptance criteria
Hazard ID/PHA
Human Factors/Usability
Analysis/Use FMEA
Risk Benefit Analysis
Risk Assessment of Complaint
Data/Customer Feedback
Degree of change:
Design, manufacturing and
labeling changes at the premarket stage.
Effectiveness of RM
RM techniques are highly
effective for all factors during
the pre-market stage (except for
saving cost).

11

Implantable

New, first generation
Not yet released – in
device marketed for first clinical trial
time
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RM techniques used:
Establish risk acceptance criteria
Human Factors/Usability

Analysis/Use FMEA
DFMEA
PFMEA
Risk Benefit Analysis
Risk Assessment of Complaint
Data/Customer Feedback
Degree of change:
Labeling and manufacturing
changes at the pre-market stage.
Some design change during
clinical validation.
Effectiveness of RM
Overall design quality is highly
effective during the pre-market
stage.
Catching problems and early
identification of product
improvements were rated highly
effective during V&V and pilot
production.
12

Implantable

New, first generation
Not yet released – in
device marketed for first clinical trial
time
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RM techniques used:
Establish risk acceptance criteria
Hazard ID/PHA
Human Factors/Usability
Analysis/Use FMEA
DFMEA

Degree of change:
Only labeling changes were
indicated from V&V.
Design and manufacturing
changes at the initial
development.

13

Therapeutic

New, first generation
Not yet released – in
device marketed for first clinical trial
time

Effectiveness of RM
Effectiveness was primarily
indicated for cost savings and
overall design quality.
RM techniques used:
Establish risk acceptance criteria
Hazard ID/PHA
Human Factors/Usability
Analysis/Use FMEA
DFMEA
PFMEA
Risk Benefit Analysis
Risk Assessment of Complaint
Data/Customer Feedback
Degree of change:
Very active design changes in
RM.

14

Unknown

Revision of previous
first generation device

18 to 36 months
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Effectiveness of RM
Rated very highly effective.
RM techniques used:
Establish risk acceptance criteria

Human Factors/Usability
Analysis/Use FMEA
DFMEA
HAZOP
HACCP
Risk Benefit Analysis
Risk Assessment of Complaint
Data/Customer Feedback
Degree of change:
Very active design changes in
RM.
Effectiveness of RM
(No response)
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Summary and Conclusion
Risk management activities are employed by medical device companies to ensure
that the intended use and purpose of the medical device are properly addressed and the
known and foreseeable hazards are well identified. Regardless of the medical device
classification, the use of the appropriate RM activities according to device type and
maturity play a significant role in determining the effectiveness of the activities utilized.
This risk management survey was conducted to understand the use and effectiveness of
the risk management activities and how these activities impact the medical device
development.
The 14 respondents may not be enough to arrive at a statistically significant
evaluation of RM activities. However, a trend is evident in the survey showing a switch
of the effectiveness ratings in the entire life cycle, and how the degree of change was
measured throughout the device phase. Therefore, these results may be used as a guide to
improve risk management practices.
A survey on the implementation and effectiveness of risk management activities
was carried out in this research to achieve an accurate assessment of how RM activities
can contribute to the level of change in the design and manufacturing processes and how
RM activities are recognized as vital to the medical device design and manufacturing
operations.
The degree of change and measure of effectiveness of RM activities based on
survey results were significantly impacted by the following factors: device type, time
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since market release, and device development history. Table 4 summarizes the RM
effectiveness based on survey results.
Further studies on the impact of RM activities in the medical device industry is
highly encouraged to achieve a better understanding of the significance that these
activities bring to influence the development of a medical device.
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Table 4: Summary of RM Effectiveness from the Survey
Device Type (Number of
respondent)

Pre-Market Effectiveness of RM Activities

Post-Market Effectiveness of RM Activities

Surgical Tools &
catheters (4)

Relatively more effective for all purposes
especially second generation devices

Some effectiveness especially for costs savings
and product improvement

Diagnostic devices (3)

Relatively more effective for early
identification and overall design quality

Relatively less effective (except for catching
problems and cost savings where RM has some
effectiveness)

Implantables (5)

Generally rated less effective than for other
device types. Most effectiveness was
indicated for overall product quality

(Not enough respondents had devices in postmarket stage)

Other therapeutic
devices (1)

Rated highly effective on all factors

(No data)
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